Assessment of circulating copy number variant detection for cancer screening

by Bhuvan Molparia, Eshaan Nichani, Ali Torkamani

Current high-sensitivity cancer screening methods, largely utilizing correlative biomarkers, suffer from false positive rates that lead to unnecessary medical procedures and debatable public health benefit overall. Detection of circulating tumor DNA (ctDNA), a causal biomarker, has the potential to revolutionize cancer screening. Thus far, the majority of ctDNA studies have focused on detection of tumor-specific point mutations after cancer diagnosis for the purpose of post-treatment surveillance. However, ctDNA point mutation detection methods developed to date likely lack either the scope or analytical sensitivity necessary to be useful for cancer screening, due to the low (

from ! ORL Sfakianakis via paythelady.61 on Inoreader http://ift.tt/2tVbNq7
via IFTTT